iBio FY26 net loss widens to $33.04 million; revenue drops to $100,000

IBIO•2026-08-28

Pipeline progress

Phase 1 IBIO-600 advanced through single ascending dose with 31 of 32 participants dosed; IBIO-610 moved into IND-enabling studies.

Higher research spending and cash position

Research and development expense climbed to USD 19.64 million on higher consultant and outside-services spending, plus a USD 2.5 million milestone.

Cash, cash equivalents and debt-security investments totaled USD 88 million at June 30, 2026; management said financings extended runway into fiscal 2028.

Fiscal 2026 results show lower revenue and wider loss

iBio posted fiscal 2026 revenue of USD 100,000, down 75%.

Net loss widened to USD 33.04 million; loss per share narrowed to USD 0.32.

iBio FY26 net loss widens to $33.04 million; revenue drops to $100,000

Pipeline progress

Higher research spending and cash position

Fiscal 2026 results show lower revenue and wider loss

Related News

Chagee Announces Second Quarter 2026 Unaudited Financial Results

Ulta Beauty <ULTA.O>: Deutsche Bank cuts target price to $671 from $695

Netcapital Receives Nasdaq Notice For Delayed FY2026 Form 10-K Filing

Nano Labs FY26 H1 net loss more than doubled to RMB 316.7 million; revenue drops 66.46% to RMB 2.8 million

Matador Resources CEO Joseph Wm Foran buys 555 common shares worth $30,242.95